ClinicalTrials.gg
RecruitingNCT06686108Updated May 7, 2025

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

A Phase 2 interventional study of Azacitidine (AZA) Days 1 - 5 and Decitabine (DAC) in T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION and Relapse, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 14 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-05-07.

Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
14 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing venetoclax in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma — 11 open to participants now, 13 under way, 1 of them phase 3. venetoclax · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
4th of 17
59 · median 28
Started
2024
with 2 others
Phase 2
9 of 17
6 open now
Primary completion
2027-10
later than 4 of 12 live
Registered
12th of 17
by date
Lead sponsor
1 of 17
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Among the 17 studies testing venetoclax in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, this one is the 4th largest by planned enrollment, is one of 3 that started in 2024, is one of 9 in phase 2, reaches primary completion later than 4 of the 12 other live ones, and was the 12th registered.

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

421 studies on the registry are indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; 75 are open to participants now.

Browse Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

11 of the 17 studies testing venetoclax in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 58 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 23 (40%) set no upper age limit and 30 (52%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.

This study: 14 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing venetoclax in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

This study is a prospective, phase II clinical trial with the primary objective of assessing the effectiveness of demethylating agents combined with venetoclax in the prevention of recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) of high risk T-lymphoblastic lymphoma/leukemia (T-LBL/ALL) patients.

Read the detailed description

The experimental group included high risk T-ALL/LBL patients after allo-HSCT, who received relapse prevention treatment with demethylating agents such as azacitidine or decitabine, combined with venetoclax.

The historical control consisted of high-risk T-ALL/LBL patients who received allo-HSCT but did not receive any prophylactic treatment from multiple centers, and their basic information, disease information, treatment details, and efficacy data were collected. Propensity score matching was conducted with historical data to compare the advantages and disadvantages of the experimental regimen with the control group.

The primary endpoint was the relapse-free survival(RFS) rate after prophylaxis, while secondary endpoints included cumulative incidence of relapse (CIR), overall survival (OS), and the GVHD-relapse-free survival (GRFS). This study aims to provide a effective and safer prophylaxis treatment for high-risk T-LBL/ALL patients after all-HSCT.

03

Conditions studied

  • T-cell Acute Lymphoblastic Leukemia
  • ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
  • Relapse

Keywords

  • T-cell lymphoblastic lymphoma/leukemia
  • relapse
  • allogeneic hematopoietic stem cell transplantation
04

Who can participate

Ages eligible
14 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.14-55 years old, male,or female.
  • 2.Patients with due to T-LBL/ALL, the donor type is not limited.
  • 3. score is 0-2 points.
  • 4.Blood routine: ≥ 1.0 × 109/L, ≥ 50 × 109/L.
  • 5.One of the following high-risk factors:
  • a. Age of initial diagnosis ≥ 35 years old.
  • b. Initial diagnosis of WBC ≥ 100 × 109/L.
  • c. Initial diagnosis of LDH exceeding the values.
  • d. Initial diagnosis of bone marrow involvement (blast cells ≥ 5%).
  • e. Initial diagnosis of a bulky in the mediastinum (longest diameter ≥ 10cm).
  • f. ETP immunophenotype.
  • g. During the induction chemotherapy process, 2 courses did not achieve partial remission and/or 4 courses did not achieve complete remission.
  • h. Residual lesions before transplantation: Flow cytometry analysis showed that the proportion of abnormal lymphoid cells in the bone marrow was greater than 0.01%; Positive detection of minimal residual lesions in molecular biology; PET-CT scan shows that residual lesions are still active.
  • i. Based on the ELN recommendation based on adult T-ALL: gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations; t (8; 14) (q24; q11)/MYC rearrangement; t (7; 19) (q34; p13)/TCR-LYL1,TCR-MEF2C; del(5q) (q14).
  • j. High risk subgroups based on NGS definition: PI3K signaling pathway/NRAS, KRAS/TP53/IKZF1/DNTM3A/IDH1, IDH2 gene mutation with or without NOTCH1, FBXW7/PHF6/EP300 gene mutation.

Exclusion criteria

Exclusion Criteria:

  • 1.Central involvement during any course of the disease.
  • 2.Patients who have not achieved complete remission before transplantation.
  • 3.Identify those with available targeted drugs.
  • 4.For those who are resistant to BCL-2 inhibitors before transplantation, if the disease progresses during the application process, or if 3-4 courses of induction therapy containing BCL2 inhibitors do not improve.
  • 5.Individuals who are known to be allergic to demethylating drugs or venetoclax.
  • 6.Individuals with grade 2 or more degrees of active acute .
  • 7.Individuals with moderate to severe chronic GVHD.
  • 8.T-LBL/ALL relapse (flow cytometry abnormal lymphocyte cell proportion>0.01%, WT1 positive, fusion gene positive, or extramedullary recurrence), or transplant rejection, bone marrow donor cell chimerism\<95%.
  • 9.Blood routine: ANC\<1.0 × 109/L or \<50 × 109/L.
  • 10.Combined with severe organ dysfunction; The ratio of (AST)/alanine aminotransferase (ALT) is more than 3 times the normal value or the normal value of direct is more than 3 times; The endogenous rate (Ccr) is less than 50mL/min or 1.5 times the normal value of blood creatinine, regardless of whether hemodialysis treatment is used.
  • 11.Merge severe active infections.
  • 12.Pregnant or lactating women.
  • 13. Accepting other drugs.
  • 14.According to the researchers' assessment, the patient may have complications that could lead to other dangers.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (estimated)

Study arms

  • Experimental
    combination therapy

    There is only 1 arm. Combination therapy arm included venetoclax combined with hypomethylating agents such as azacitidine or decitabine. 1. venetoclax: 400mg/d, po, days 1-7 of each 28-day cycle. 2.For patients without TP53 mutation, azacitidine was administered: 32mg/m2/d, ih, days 1-5 of each 28-day cycle; for patients with TP53 mutation, decitabine was administered: 5mg/m2/d, iv, days 1-5 of each 28-day cycle.

    Drug: Azacitidine (AZA) Days 1 - 5 · Drug: Decitabine (DAC) · Drug: Venetoclax

Interventions

  • DrugAzacitidine (AZA) Days 1 - 5

    Azacitidine, ih, 32mg/m2/d, days 1-5 of each 28-day cycle

  • DrugDecitabineStudies of DecitabineDecitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    decitabine, 5mg/m2/d, days 1-5 of each 28-day cycle.

  • venetoclax, 400mg/d, days 1-7 of each 28-day cycle

06

What researchers measure

Primary outcomes

  1. RFS

    1-year relapse-free survival

    Time frame: 1 year

  2. RFS

    2-year relapse-free survival

    Time frame: 2 year

Secondary outcomes

  1. CIR

    1-year cumulative incidence of relapse

    Time frame: 1 year

  2. CIR

    2-year cumulative incidence of relapse

    Time frame: 2 year

  3. OS

    1-year overall survival

    Time frame: 1 year

  4. OS

    2-year overall survival

    Time frame: 2 year

  5. GRFS

    1-year graft-versus-host disease (GVHD)-free/relapse-free survival (GRFS) rates

    Time frame: 1 year

  6. GRFS

    2-year graft-versus-host disease (GVHD)-free/relapse-free survival (GRFS) rates

    Time frame: 2 year

  7. cGVHD

    1-year cumulative incidence of cGVHD

    Time frame: 1 year

  8. cGVHD

    2-year cumulative incidence of cGVHD

    Time frame: 2 year

  9. adverse events

    adverse events during research

    Time frame: at the end of every cycle (each cycle is 28 days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.

Of 40 non-industry phase 2 interventional studies under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 97. This study's planned 36 months is below that.

Counting every sponsor, half of 43 studies reached it within 63 months; a quarter within 39 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2024
First posted
Nov 13, 2024
StartActual
Oct 30, 2024
Primary completionEst.
Oct 30, 2027
CompletionEst.
Oct 30, 2028
Last update
May 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06686108
Responsible party
Xianmin Song, MD (Professor, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Nov 13, 2024
Start date
Oct 30, 2024
Primary completion
Oct 30, 2027 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
May 7, 2025

Study contacts

Xianmin Song
Contact
shongxm@139.com
+8613501672508

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion